Kidney Week Educational Symposia-Is It Time to Target Complement in IgAN?

Video Transcription

Video Summary

<strong style="box-sizing: border-box; font-weight: bold; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Moderator(s):</strong><span style="color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff; float: none; display: inline;"> Chi-yuan Hsu</span><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" /><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" /><strong style="box-sizing: border-box; font-weight: bold; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Presentation(s):</strong><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" />
<ul style="box-sizing: border-box; margin-top: 0px; margin-bottom: 10px; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Introduction</strong> - Chi-yuan Hsu</li>
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Complement Pathways in the Pathogenesis of IgAN</strong> - Mark Haas</li>
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Integrating New Anticomplement Drugs into the Treatment of IgAN: A Precision-Medicine Approach</strong> - Ladan Zand</li>
</ul>
<em>Support is provided by educational grants from Alexion, AstraZeneca Rare Disease and Novartis Pharmaceuticals Corporation.</em>&nbsp;

Asset Subtitle

Moderator(s): Chi-yuan Hsu

Presentation(s):

Introduction - Chi-yuan Hsu
Complement Pathways in the Pathogenesis of IgAN - Mark Haas
Integrating New Anticomplement Drugs into the Treatment of IgAN: A Precision-Medicine Approach - Ladan Zand

Support is provided by educational grants from Alexion, AstraZeneca Rare Disease and Novartis Pharmaceuticals Corporation.

Meta Tag

Pathway(s) Glomerular Diseases

Pathway(s) Pathology

Session Type ES - Educational Symposium

Speaker(s) Chi-yuan Hsu

Speaker(s) Mark Haas

Speaker(s) Ladan Zand

Keywords

IgA nephropathy

complement inhibition

alternative pathway

lectin pathway

ip tacopan

factor B inhibitor

proteinuria

C4d biomarker

kidney outcomes

IgAN

complement pathways

pathogenesis

anticomplement drugs

precision medicine

treatment

nephrology

Mark Haas